Skip to main content
PharmaResources (Shanghai) Co., Ltd. logo

PharmaResources (Shanghai) Co., Ltd. — Investor Relations & Filings

Ticker · 301230 ISIN · CNE1000065Q9 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 458 across all filing types
Latest filing 2025-03-04 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 301230

About PharmaResources (Shanghai) Co., Ltd.

https://www.pharmaresources.cn

PharmaResources (Shanghai) Co., Ltd. is a comprehensive Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) specializing in small molecule drug discovery and development. The company provides an integrated platform of services including medicinal chemistry, custom synthesis, process research and development, and analytical chemistry. PharmaResources supports global pharmaceutical and biotechnology partners through the entire drug development lifecycle, from initial lead optimization to the commercial-scale manufacturing of advanced intermediates and Active Pharmaceutical Ingredients (APIs). With a focus on technical innovation and quality management, the firm utilizes advanced synthetic methodologies and process engineering to accelerate drug candidates toward clinical trials and market approval.

Recent filings

Filing Released Lang Actions
关于为子公司开原泓博银行授信提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's decision to provide a guarantee for a subsidiary's bank credit. It includes details about the guarantee amount, the subsidiary's financial data, and the board's approval. There is no financial report or detailed financial statements presented, nor is it a transcript, presentation, or regulatory certification. The document is a formal announcement of a corporate action related to financing support for a subsidiary, which fits best under Capital/Financing Update (CAP). The document length is short (1861 characters), and it is not merely announcing the publication of a report but providing substantive information about the guarantee. Therefore, the classification is CAP with high confidence.
2025-03-04 Chinese
第三届监事会第十六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It details the election of candidates for the fourth Supervisory Board, including voting results and procedural compliance. The document is a formal announcement of board/management changes, specifically related to the Supervisory Board election and nomination. It does not contain financial data, audit information, or detailed reports, but rather announces management/board changes. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused on board election results, not a full report or regulatory filing. Confidence is high due to clear content and context.
2025-03-04 Chinese
上海泓博智源医药股份有限公司独立董事提名人声明与承诺（尤启冬）
Board/Management Information Classification · 100% confidence The document is a formal statement and commitment regarding the nomination of an independent director candidate for the company's board. It details the nominee's qualifications, compliance with regulatory requirements, and various declarations about independence and eligibility. There are no financial statements, earnings data, or report attachments. The content focuses on board/management information, specifically about director nomination and related compliance. The document length is short (2732 characters) and it is not an announcement of a report publication but a direct statement about board nomination. Therefore, the appropriate classification is Board/Management Information (MANG).
2025-03-04 Chinese
关于预计2025年度日常性关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. regarding the expected daily related-party transactions for the fiscal year 2025. It includes details about the nature of the transactions, pricing principles, related parties, independent directors' opinions, and the board's approval. The document is a formal disclosure about anticipated related-party transactions, which is a regulatory announcement rather than a full financial report or audit. It does not contain comprehensive financial statements or detailed financial analysis. The document length is 3884 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits best into the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2025-03-04 Chinese
上海泓博智源医药股份有限公司独立董事候选人声明与承诺（程立）
Board/Management Information Classification · 95% confidence The document is a formal declaration and commitment statement by an independent director candidate for a company's board. It details the candidate's qualifications, compliance with regulatory requirements, and commitments related to the role of an independent director. There are no financial statements, earnings data, or report summaries present. The document is not an announcement of a report publication but a declaration related to board/management information. Therefore, the document fits the category of Board/Management Information (MANG). The document length is short and focused on director candidacy and compliance, confirming this classification.
2025-03-04 Chinese
上海泓博智源医药股份有限公司独立董事提名人声明与承诺（程立）
Board/Management Information Classification · 95% confidence The document is a formal statement regarding the nomination and qualifications of an independent director candidate for the company's board. It includes detailed declarations and commitments about the nominee's compliance with legal and regulatory requirements for independent directors. There is no financial data, earnings information, or report publication mentioned. The content focuses on board/management information, specifically about director nomination and qualifications. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is 2687 characters, which is consistent with a detailed announcement rather than a full report.
2025-03-04 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.